Andrea L Schaffer

List of Publications by Year
in descending order

68 papers	1,431 citations	516561 16 h-index	377752 34 g-index
73 all docs	73 docs citations	73 times ranked	1931 citing authors

#	Article	IF	Citations
1	Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Medical Research Methodology, 2021, 21, 58.	1.4	252
2	The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Research Notes, 2015, 8, 634.	0.6	220
3	Emergency department visits, ambulance calls, and mortality associated with an exceptional heat wave in Sydney, Australia, 2011: a time-series analysis. Environmental Health, 2012, 11, 3.	1.7	121
4	Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction, 2019, 114, 1026-1034.	1.7	75
5	Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporosis International, 2014, 25, 1345-1355.	1.3	54
6	The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?. Medical Journal of Australia, 2015, 202, 591-594.	0.8	53
7	Codeine use and harms in Australia: evaluating the effects of reâ€scheduling. Addiction, 2020, 115, 451-459.	1.7	47
8	Changes in antibiotic prescribing following COVIDâ€19 restrictions: Lessons for postâ€pandemic antibiotic stewardship. British Journal of Clinical Pharmacology, 2022, 88, 1143-1151.	1.1	37
9	Interrupted Time Series Analysis of the Effect of Rescheduling Alprazolam in Australia. JAMA Internal Medicine, 2016, 176, 1223.	2.6	31
10	Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophrenia Research, 2020, 220, 106-115.	1.1	30
11	Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. PLoS ONE, 2018, 13, e0208824.	1.1	29
12	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 716-722.	1.1	24
13	Changes in sales of analgesics to pharmacies after codeine was rescheduled as a prescription only medicine. Medical Journal of Australia, 2020, 212, 321-327.	0.8	24
14	Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006â€2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiology and Drug Safety, 2020, 29, 913-922.	0.9	23
15	Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP). Cancer Epidemiology, 2019, 60, 156-161.	0.8	19
16	Changes in antidepressant use in Australia: A nationwide analysis (2015â€"2021). Australian and New Zealand Journal of Psychiatry, 2023, 57, 49-57.	1.3	18
17	Pregabalin prescribing patterns in Australian general practice, 2012â€"2018: a cross-sectional study. BJGP Open, 2021, 5, bjgpopen20X101120.	0.9	17
18	Who benefits from fixedâ€dose combinations? Twoâ€year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiology and Drug Safety, 2017, 26, 1465-1473.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. Clinical Pharmacology and Therapeutics, 2021, 109, 212-221.	2.3	16
20	An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. Cancer Epidemiology, 2014, 38, 460-464.	0.8	14
21	Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case–control study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 2015, 39, 585-592.	0.8	14
22	Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study. Osteoporosis International, 2015, 26, 543-551.	1.3	14
23	Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children?. Journal of Paediatrics and Child Health, 2007, 43, 579-580.	0.4	13
24	How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population–based study (2006–2014). British Journal of Clinical Pharmacology, 2016, 82, 1134-1145.	1.1	13
25	Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. BMJ Quality and Safety, 2020, 29, 365-373.	1.8	12
26	The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians. BMJ Open, 2014, 4, e004099.	0.8	11
27	Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 2015, 39, 578-584.	0.8	11
28	Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in Australia. JAMA Network Open, 2019, 2, e1911590.	2.8	11
29	Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study. Journal of Geriatric Oncology, 2021, 12, 930-936.	0.5	11
30	Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study. The Lancet Regional Health - Western Pacific, 2021, 14, 100226.	1.3	11
31	Psychotropic medicine prescribing and polypharmacy for people with dementia entering residential aged care: the influence of changing general practitioners. Medical Journal of Australia, 2021, 215, 130-136.	0.8	10
32	Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. Cmaj, 2018, 190, E355-E362.	0.9	9
33	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). British Journal of Cancer, 2019, 121, 904-911.	2.9	9
34	Patterns of pregabalin initiation and discontinuation after its subsidy in Australia. British Journal of Clinical Pharmacology, 2020, 86, 1882-1887.	1.1	9
35	Trajectories of antipsychotic use before and during pregnancy and associated maternal and birth characteristics. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1208-1221.	1.3	8
36	Evidence–Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2019, 8, e014287.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Potentially inappropriate benzodiazepine use in Australian adults: A population‐based study (2014–2017). Drug and Alcohol Review, 2020, 39, 575-582.	1.1	8
38	Adherence to Antiretroviral Regimens in Australia: A Nationwide Cohort Study. AIDS Patient Care and STDs, 2020, 34, 81-91.	1.1	8
39	The impact of influenza A(H1N1)pdm09 compared with seasonal influenza on intensive care admissions in New South Wales, Australia, 2007 to 2010: a time series analysis. BMC Public Health, 2012, 12, 869.	1.2	7
40	The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 439-446.	0.9	7
41	Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. Lung Cancer, 2022, 166, 40-48.	0.9	7
42	Health-related predictors of cancer registry-notified cancer of unknown primary site (CUP). Cancer Epidemiology, 2019, 61, 1-7.	0.8	6
43	Increases in controlled‐release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population‐based study. Pharmacoepidemiology and Drug Safety, 2019, 28, 97-105.	0.9	6
44	Evidence‐practice gaps in P2Y$_{12}$ inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population‐level data linkage in Australia. Internal Medicine Journal, 2022, 52, 249-258.	0.5	6
45	Australian Suicide Prevention using Health-Linked Data (ASHLi): Protocol for a population-based case series study. BMJ Open, 2020, 10, e038181.	0.8	6
46	Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP). PLoS ONE, 2020, 15, e0230373.	1.1	6
47	The changing face of Australian data reforms: Impact on pharmacoepidemiology research. International Journal of Population Data Science, 2021, 6, 1418.	0.1	6
48	Prescribed medicine use and extent of off‐label use according to age in a nationwide sample of Australian children. Paediatric and Perinatal Epidemiology, 2022, 36, 726-737.	0.8	6
49	Validating a proxy for disease progression in metastatic cancer patients using prescribing and dispensing data. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e246-e252.	0.7	5
50	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS ONE, 2022, 17, e0269482.	1.1	5
51	Embracing the full spectrum of real‐world data for cancer medicines research in Australia. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 186-187.	0.7	3
52	Antiplatelet therapy within 30 days of percutaneous coronary intervention with stent implantation. Medical Journal of Australia, 2020, 213, 124-125.	0.8	2
53	Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study. Breast Cancer Research and Treatment, 2021, 187, 893-902.	1.1	2
54	Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use. Pain, 2022, 163, e614-e621.	2.0	2

#	Article	IF	Citations
55	Coming to grips with seemingly conflicting results in programme evaluation: the devil's in the detail. BMJ Quality and Safety, 2021, 30, 70-71.	1.8	1
56	Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study. Public Health Research and Practice, 2015, 25, e2521518.	0.7	1
57	Gabapentinoids: repeating mistakes of the past?. Addiction, 0, , .	1.7	1
58	Monitoring emerging prescription drug related harms: a comment on Cairns <i>et al</i>. (2018)—in reply. Addiction, 2019, 114, 572-573.	1.7	0
59	Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate. Pharmacoepidemiology and Drug Safety, 2019, 28, 521-527.	0.9	0
60	Patterns of opioid use in older people diagnosed with cancer in New South Wales, Australia. Pharmacoepidemiology and Drug Safety, 2021, 30, 360-370.	0.9	0
61	Real-world data to advance HER2-targeted cancer medicines research: Playing to the strengths of clinical registry and administrative data. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 414-415.	0.7	0
62	Using Australia's National Data Linkage Demonstration Project (NDLDP) to improve cardiac care: Towards a national, whole-of-population linked data resource for evidence-informed health policy. International Journal of Population Data Science, 2018, 3, .	0.1	0
63	Assessing the impact of implementing multiple adherence measures to antiretroviral therapy from dispensing data: a short report. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, , 1-6.	0.6	0
64	The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2022, 31, 370-378.	0.9	0
65	Title is missing!. , 2020, 15, e0230373.		0
66	Title is missing!. , 2020, 15, e0230373.		0
67	Title is missing!. , 2020, 15, e0230373.		0
68	Title is missing!. , 2020, 15, e0230373.		0